Ultragenyx Pharmaceutical Inc - ESG Rating & Company Profile powered by AI
Detailed Sustainability analysis of Ultragenyx Pharmaceutical Inc can be reached by signing in. Alternative corporations in the scoring peer group for Ultragenyx Pharmaceutical Inc are displayed. The Disclosure rating includes seventeen United Nations SDGs including: 'No Poverty', 'Climate Action' and 'Partnerships for the Goals'.
Ultragenyx Pharmaceutical Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.2; made up of an environmental score of 8.0, social score of 6.9 and governance score of 6.7.
7.2
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
191 | Wockhardt Ltd | 7.3 | High |
191 | Zealand Pharma A/S | 7.3 | High |
217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
217 | Eurofins Scientific SE | 7.2 | High |
217 | Dermapharm Holding SE | 7.2 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Ultragenyx Pharmaceutical Inc have an accelerator or VC vehicle to help deliver innovation?
Does Ultragenyx Pharmaceutical Inc disclose current and historical energy intensity?
Does Ultragenyx Pharmaceutical Inc report the average age of the workforce?
Does Ultragenyx Pharmaceutical Inc reference operational or capital allocation in relation to climate change?
Does Ultragenyx Pharmaceutical Inc disclose its ethnicity pay gap?
Does Ultragenyx Pharmaceutical Inc disclose cybersecurity risks?
Does Ultragenyx Pharmaceutical Inc offer flexible work?
Does Ultragenyx Pharmaceutical Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Ultragenyx Pharmaceutical Inc disclose the number of employees in R&D functions?
Does Ultragenyx Pharmaceutical Inc conduct supply chain audits?
Does Ultragenyx Pharmaceutical Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Ultragenyx Pharmaceutical Inc conduct 360 degree staff reviews?
Does Ultragenyx Pharmaceutical Inc disclose the individual responsible for D&I?
Does Ultragenyx Pharmaceutical Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Ultragenyx Pharmaceutical Inc disclose current and / or historical scope 2 emissions?
Does Ultragenyx Pharmaceutical Inc disclose water use targets?
Does Ultragenyx Pharmaceutical Inc have careers partnerships with academic institutions?
Did Ultragenyx Pharmaceutical Inc have a product recall in the last two years?
Does Ultragenyx Pharmaceutical Inc disclose incidents of discrimination?
Does Ultragenyx Pharmaceutical Inc allow for Work Councils/Collective Agreements to be formed?
Has Ultragenyx Pharmaceutical Inc issued a profit warning in the past 24 months?
Does Ultragenyx Pharmaceutical Inc disclose parental leave metrics?
Does Ultragenyx Pharmaceutical Inc disclose climate scenario or pathway analysis?
Does Ultragenyx Pharmaceutical Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Ultragenyx Pharmaceutical Inc disclose the pay ratio of women to men?
Does Ultragenyx Pharmaceutical Inc support suppliers with sustainability related research and development?
Does Ultragenyx Pharmaceutical Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Ultragenyx Pharmaceutical Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Ultragenyx Pharmaceutical Inc involved in embryonic stem cell research?
Does Ultragenyx Pharmaceutical Inc disclose GHG and Air Emissions intensity?
Does Ultragenyx Pharmaceutical Inc disclose its waste policy?
Does Ultragenyx Pharmaceutical Inc report according to TCFD requirements?
Does Ultragenyx Pharmaceutical Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Ultragenyx Pharmaceutical Inc disclose energy use targets?
Does Ultragenyx Pharmaceutical Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Ultragenyx Pharmaceutical Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Ultragenyx Pharmaceutical Inc
These potential risks are based on the size, segment and geographies of the company.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.